Biocompounds Pharmaceutical Inc.

Established in 2003, Biocompounds Pharmaceutical Inc. (hereinafter referred to as "BPI") is an innovative corporation based on chemical sciences, committed to licensed production in the field of pharmaceutical and agrochemical and customized research and development of new drugs for major domestic and international pharmaceutical companies. BPI completed the wholly-owned acquisition of Anhui Biocompounds Chemicals Co., Ltd (formerly "Anhui Changtai chemical", hereinafter referred to as "Anhui Biocompounds Chemicals") at the end of 2016 and Anhui Biocompounds Pharmaceutical Co.,Ltd (formerly "Anhui Envii Pharmaceutical Co., Ltd. ", hereinafter referred to as "Anhui Biocompounds Pharmaceutical") in the August of 2018. It marks the prelude to BPI’s official transformation from a technology-based R&D company to a high-tech manufacturing enterprise integrating R&D, manufacturing and sales of medicine and pesticides.

Deriving from oncology studying team of SIMM, Chinese Academy of Sciences, committed to the development of various antitumor drugs, with professional and efficient R&D and technical support teams, BPI has carried out innovative projects cooperation and talent exchange and training together with Fudan University, Shanghai Institute of Materia Medica, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, East China Normal University, East China University of Science and Technology，Shanghai University of Engineering Science, Shanghai Institute of Technology, Hefei University of Technology, Anqing Normal University, and Chizhou University. Over the years, we have always regarded technological innovation as the forerunner and quality as the core. We have accumulated rich experience while constantly consolidating our own foundation in the industry, team, manufacturing and service. In terms of market extension and industrial development, BPI has taken various approaches such as technical services, strategic cooperation, channel development, product management, etc. to actively explore its own development, expansion, upgrading and transformation in the process of creating value and solving pain points for customers. We have always attached great importance to the cultivation of young team and innovation ability, constantly strengthened the talent reserve and team training, and made greater efforts to create a working and living environment suitable for modern youngers. Thanks to more and more excellent members joining us, we have brought and left many wonderful chapters in different value chains. In 2017, BPI established academician and expert workstation in Shanghai, established small molecular targeted drug research institute in Anhui in the September of 2018, completed the pilot cultivation of small giants and joined Songjiang G60 scientific and technological innovation enterprises in 2019, which provides a broader space and more attractive growth platform for the company's future and young technical staff to take root in BPI and to create a brilliant future.

At present, BPI and its two wholly-owned subsidiaries have a total of nearly 450 employees. The first phase project of the plant is under orderly production. The second phase project is under construction and gradually realize the trial production of workshop scale. In 2019, under the environment of “4 + 7”, BPI will take "layout of high-end generic drugs, deep excavation of green production routes and improvement of product quality" as its long-term goal, and take its member enterprises to actively cooperate with domestic pharmaceutical companies to build a green pharmaceutical platform and promote more CDMO / CMO development. Two of the factories in Dongzhi, Anhui Province, have a total area of more than 400 Chinese acres, with equipment and production lines with a variety of qualifications for the use of hazardous chemicals and a variety of hazardous reactions . On this basis, we will increase investment in technology and safety, cooperate with the most advanced safety, environmental protection and equipment platform, and brand the initial design of the process route with "green", "safe", "efficient" and "people friendly", so as to create a high standard point of API and intermediate production platform.

At the same time, we actively carry out research, production and cooperation of drugs and their advanced intermediates under the MAH / GMP standard in Shanghai and Anhui, and strive to build our chemical pharmaceutical standardization platform and provide strong support for the pharmaceutical industry.